The DREAMSeq trial ECOG-ACRIN EA 6134 involved the treatment of metastatic BRAFV600-mutant melanoma patients with two different sequences of BRAF/MEK inhibitors and nivolumab/ipilimumab; patients treated first with nivolumab/ipilimumab and then dabrafenib/trametinib had a better PFS and OS compared to those treated first with dabrafenib and trametinib and then with nivolumab/ipilimumab [103]. Here, BRAF is linked to melanoma.